Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

AstraZeneca-Oxford COVID-19 vaccine supply hits two billion doses

Published 16/11/2021, 00:12
Updated 16/11/2021, 00:16
© Reuters. FILE PHOTO: A woman reacts as she receives an AstraZeneca/Oxford coronavirus disease (COVID-19) vaccine, donated to Kenya by the UK government, in Nairobi, Kenya, August 8, 2021. REUTERS/Baz Ratner

© Reuters. FILE PHOTO: A woman reacts as she receives an AstraZeneca/Oxford coronavirus disease (COVID-19) vaccine, donated to Kenya by the UK government, in Nairobi, Kenya, August 8, 2021. REUTERS/Baz Ratner

(Reuters) - Two billion doses of the AstraZeneca-Oxford University COVID-19 vaccine have been supplied worldwide, the Anglo-Swedish drugmaker and its partner said on Tuesday, in just under a year since its first approval.

The shot, which is the biggest contributor to the COVAX vaccine sharing scheme backed by the World Health Organization, is being made in 15 countries for supply to more than 170 countries, London-listed AstraZeneca (NASDAQ:AZN) and Oxford University said in a joint statement.

AstraZeneca in June last year signed on India's Serum Institute, the world's biggest manufacturer of vaccines by volume, to help double the vaccine's manufacturing capacity to two billion doses.

The ChAdOx1 nCoV-19 shot, sold under the brand names Vaxzevria and Covishield, has faced challenges around efficacy data, supplies and links to rare blood clots.

© Reuters. FILE PHOTO: A woman reacts as she receives an AstraZeneca/Oxford coronavirus disease (COVID-19) vaccine, donated to Kenya by the UK government, in Nairobi, Kenya, August 8, 2021. REUTERS/Baz Ratner

AstraZeneca last week said as the world learns to live with the coronavirus which causes COVID-19, it would begin to earn a modest profit from the shot after having made a commitment to sell it at cost during the pandemic.

The company's chief executive officer, Pascal Soriot, however, reassured that low-income countries would continue to receive vaccines on a non-profit basis.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.